Advice
Not recommended for use within the NHS in Scotland.
REASONS FOR ADVICE
This drug reduces blood sugar to a greater extent after breakfast and evening meal, but to a lesser extent after lunch, than existing treatment. It has no clear advantage in terms of global glycaemic control as demonstrated by HbA1c. There is no reduction in hypoglycaemic episodes to justify the overall increase in cost.
Download detailed advice10KB (PDF)
Medicine details
- Medicine name:
- Biphasic insulin aspart 30 (Novomix 30®)
- SMC ID:
- 06/02
- Indication:
- Diabetes mellitus
- Pharmaceutical company
- Novo Nordisk Ltd
- BNF chapter
- Endocrine system
- Submission type
- Full
- Status
- Not recommended
- Date advice published
- 05 July 2002